secwatch.observer — SEC 8-K summary
======================================

Issuer:     Replimune Group, Inc. (REPL)
CIK:        0001737953
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001104659-23-000666
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Replimune appoints Chris Sarchi as CCO and Sushil Patel as Chief Strategy Officer, effective immediately
--------------------------------------------------------------------------------

- Chris Sarchi, former Sanofi U.S. Commercial Oncology Head, named Chief Commercial Officer.
- Sushil Patel, previously CCO, transitions to newly created Chief Strategy Officer role.
- Appointments aim to ramp up commercial planning ahead of potential 2024 launch of RP1.
- Sarchi led Libtayo launch in CSCC; Patel will lead ex-U.S. strategy and platform planning.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923000666/0001104659-23-000666-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737953/000110465923000666/tm231486d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-000666

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer